The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Cardiogen
To understand any Khavinson bioregulator, you must first understand the theoretical framework that underlies all of them. The theory is specific, the evidence for it is real, and the extent of its clinical validation varies dramatically across the compound series.
Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology have, since the 1970s, developed and studied a class of short peptides (2-4 amino acids) they call 'bioregulators' or 'cytomeds.' The central hypothesis: specific short peptides derived from particular tissues regulate gene expression in a tissue-specific way. A tetrapeptide derived from cardiac tissue regulates cardiac cell function; one from brain tissue regulates neuronal function; one from cartilage regulates chondrocyte function. The mechanism proposed: these peptides enter the cell nucleus and interact with regulatory DNA elements (gene promoters), modulating transcription of tissue-relevant genes. Khavinson's 2021 review in Biomedicine & Pharmacotherapy (Peptide Regulation of Gene Expression: A Systematic Review) documents this gene regulation hypothesis with supporting data.
The Khavinson research program produced a series of organ-specific bioregulators. Some are defined single peptides (e.g., Epithalon = AEDG; Cardiogen = AEDR; Bronchogen = AEDL; Crystagen = KEDW). Others are heterogeneous polypeptide extracts from organ tissue (e.g., Cortexin = bovine/porcine cortex polypeptide mixture; Thymalin = thymic polypeptide extract). The evidence architecture for all of them shares common features: Khavinson group primary research; Russian clinical program data; limited Western peer-review replication; Russian pharmaceutical approval where it exists.
THE SHARED CENTRAL TENSION FOR ALL FOUR COMPOUNDS
Each Khavinson bioregulator in this chapter faces the same fundamental evidence evaluation challenge: the research supporting these compounds originates predominantly from one institution (St. Petersburg Institute of Bioregulation and Gerontology) and its affiliated researchers. This does not mean the evidence is fabricated — some findings have been replicated, the gene regulation mechanism has independent theoretical support, and Cortexin specifically has Russian pharmaceutical approval based on clinical trial data. But single-institution provenance means independent replication is limited, the claims have not been stress-tested by adversarial review, and Western systematic reviewers generally cannot access or fully evaluate the primary Russian-language publications. Grade the evidence accordingly.
Crystagen is the Khavinson bioregulator targeted at connective tissue and cartilage. As a tissue-specific bioregulator in the Cytogen series, it is designed to support chondrocyte and connective tissue cell function.
Crystagen (Lys-Glu-Asp-Trp; KEDW) is a synthetic tetrapeptide from the Cytogen bioregulator series. Target tissue: connective tissue, cartilage, joints. Xcells carries it. The KEDW sequence was derived from connective tissue peptide fractions following the Khavinson methodology of identifying minimum active sequences from tissue extracts.
The Khavinson group's research: Crystagen proposed to regulate chondrocyte and connective tissue fibroblast gene expression via the same DNA-binding peptide mechanism proposed for the other Cytogen bioregulators. Supporting in vitro tissue culture evidence from the Khavinson group shows effects on collagen synthesis and connective tissue cell activity. Community indication: joint health, cartilage support, connective tissue aging. The connective tissue indication is pharmacologically consistent with the Khavinson tissue-specificity hypothesis but has less published clinical data than Cortexin.
Grade C (animal and in vitro; Khavinson group primary). No independent Western peer-reviewed studies. No human clinical trials specifically for Crystagen. The evidence architecture is the standard Cytogen series template: tissue culture data, animal studies, Khavinson group publication, limited Western replication.
Compound
Type
Sequence/Composition
Target Tissue
Russian Status
Vendor
Cortexin
Polypeptide extract (MW 1,000-10,000 Da heterogeneous mixture)
Multiple low-MW neuropeptides from bovine/porcine cerebral cortex
Brain / CNS
Approved pharmaceutical (Geropharm; stroke, TBI, encephalopathy, epilepsy, cognitive disorders, pediatric developmental delay)
B (limited human; Russian approval based on clinical trials)
Limitless
CardioCytogen (Cardiogen)
Defined synthetic tetrapeptide (MW ~430 Da)
Ala-Glu-Asp-Arg (AEDR)
Heart / cardiomyocytes / cardiac fibroblasts
Research use; not independently approved as CardioCytogen; Cardiogen studied in Khavinson program
C (animal + in vitro; Khavinson group)
Limitless
Crystagen
Defined synthetic tetrapeptide (MW ~580 Da est.)
Lys-Glu-Asp-Trp (KEDW)
Connective tissue / cartilage / joints
Research use; part of Cytogen series
C (animal + in vitro; Khavinson group)
Xcells
Bronchogen
Defined synthetic tetrapeptide (MW ~476 Da est.)
Ala-Glu-Asp-Leu (AEDL)
Bronchial / pulmonary epithelium
Research use; part of Cytogen series
C (animal + in vitro; Khavinson group)
Limitless
Cortexin is the only compound in this cluster with a Russian pharmaceutical approval and substantial clinical trial data. It is also the most pharmacologically complex — a heterogeneous mixture of polypeptides rather than a defined single compound.
Cortexin is a lyophilized polypeptide complex extracted from the cerebral cortex of cattle or pigs, manufactured by Geropharm (St. Petersburg, Russia). It contains water-soluble polypeptide fractions with molecular weights of 1,000-10,000 Da stabilized with glycine — not a single defined compound but a complex mixture of naturally occurring neuropeptides. Administered by intramuscular injection (standard) or intranasally (community use; 0.5-3 mg/day). The composition is characterized by polypeptide molecular weight fractions and neurotrophic activity, not by a defined amino acid sequence.
This heterogeneity distinguishes Cortexin from Cerebrolysin (pig brain-derived polypeptide mixture, widely studied for neuroprotection in stroke and dementia) and from single-peptide bioregulators like Cardiogen. As a tissue extract, Cortexin's activity depends on the sum of its multiple peptide components rather than a single mechanism. Molecular partnership analysis has identified β5-tubulin, creatine kinase B, and protein 14-3-3 α/β as specific molecular targets of Cortexin peptides in brain tissue.
Receptor pharmacology characterization via in vitro assays: Cortexin's polypeptide components interact with AMPA receptors, kainate receptors, mGluR1 (metabotropic glutamate), GABA₂A1, and mGluR5. This multi-receptor profile reflects the composition diversity of the extract — different peptide fractions activate different receptor systems. AMPA receptor modulation is particularly pharmacologically relevant: AMPA receptors mediate fast excitatory neurotransmission; positive modulation (as with ampakines and compounds like Noopept) is associated with cognitive enhancement; AMPA overactivation is associated with excitotoxicity. Cortexin's AMPA interaction in the context of its other anti-excitotoxic and antioxidant effects creates a complex neuroprotective profile.
Russian approval: Cortexin is approved in Russia for ischemic stroke, traumatic brain injury (TBI), encephalopathy, epilepsy, cognitive disorders in adults, and pediatric developmental delay. This approval is based on Russian clinical trials conducted primarily by Geropharm and affiliated institutions. A 2025 preclinical study (Biomedicines; PMC12024793) confirmed neurotropic effects in rat models of neonatal ischemia-hypoxia and toxic CNS damage, showing cell survival promotion in cortical regions. Comparative preclinical: Cortexin at 1-3 mg/kg demonstrated neuroprotective efficacy comparable to Cerebrolysin and Actovegin in models of acute and chronic brain ischemia. A 2025 study in rat cerebral ischemia-reperfusion showed Cortexin reduced total oxidant status (TOS), increased total antioxidant status (TAS), and decreased OPG/RANK/RANKL inflammatory signaling and TRPC1 calcium channel expression.
Both Cortexin and Cerebrolysin are neuroprotective polypeptide brain extracts; they differ in source (Cortexin = cortex tissue specifically; Cerebrolysin = whole brain), species (Cortexin = bovine/porcine cortex; Cerebrolysin = porcine whole brain), route (Cortexin = IM or intranasal; Cerebrolysin = IV), and evidence base (Cerebrolysin has more independent Western-accessible trials; Cortexin is more Russia-specific). Cortexin was the source material from which the defined single-peptide bioregulators Cortagen (AEDP) and Pinealon (EDR) were derived by directed synthesis — Khavinson's approach of identifying the minimum active sequence from complex extracts.
Limitless carries Cortexin. Community: intranasal delivery preferred for blood-brain barrier access (standard Russian clinical protocol uses IM injection; intranasal bypasses systemic metabolism). Doses: 0.5-3 mg/day intranasal; cycled (2-4 weeks on; 2 weeks off). Effects reported: cognitive clarity, neuroprotective support, some users report benefit in post-TBI cognitive symptoms. No independent Western community pharmacokinetic data exists.
CardioCytogen is a defined tetrapeptide (Ala-Glu-Asp-Arg) from the Khavinson cardiac bioregulator series. It is the synthetic version of what the Khavinson group studied as 'Cardiogen.' The research evidence is animal and in vitro only.
CardioCytogen (Cardiogen; H-Ala-Glu-Asp-Arg-OH; AEDR; MW ~430 Da) is a tetrapeptide with a defined amino acid sequence. It is part of the Cytogen bioregulator series developed by Khavinson et al. from cardiac tissue peptide extracts. The sequence AEDR was identified as a minimum active peptide from cardiac tissue capable of modulating cardiac cell activity. Limitless carries it as a 20mg vial.
Proposed mechanism: Ala-Glu-Asp-Arg modulates fibroblast activity and cardiomyocyte proliferation in cardiovascular models. Chalisova et al. (2009, Advances in Gerontology) showed effects of Cardiogen on myocardial tissue culture from young and old rats. Research suggests Cardiogen influences collagen and elastin synthesis in cardiac fibroblasts — relevant to cardiac remodeling and post-infarction fibrosis. The Khavinson gene regulation hypothesis: AEDR enters cardiomyocyte nuclei and modulates expression of cardiac-relevant genes via promoter-binding interaction.
Research by Levdik and Knyazkin (St. Petersburg Institute) documented a 'tumor-modifying effect' of Cardiogen in rats with transplanted M-1 sarcoma: concentration-dependent inhibition of tumor growth attributed to hemorrhagic necrosis development and increased tumor cell apoptosis compared to control groups. This finding warrants a caution note: a compound that modulates fibroblast activity and apoptosis in tumor contexts has uncertain implications for cancer biology in general. The active malignancy caution noted for CardioCytogen reflects this, though the mechanism is not angiogenic.
Community use is limited and emerging. Limitless carries it (20mg vials). No established dosing protocol exists in the community; Khavinson animal research doses and timing provide indirect guidance. The cardiac indication — cardiomyocyte support, anti-fibrotic, cardiac remodeling — is the community rationale for use.
Bronchogen is the Khavinson bioregulator targeted at bronchial and pulmonary epithelial tissue. The AEDL tetrapeptide represents the minimal active sequence identified from pulmonary tissue extracts.
Bronchogen (Ala-Glu-Asp-Leu; AEDL) is a synthetic tetrapeptide. Note the structural relationship to Cardiogen (AEDR) and the Khavinson series convention: many Cytogen bioregulators share an Ala-Glu-Asp- N-terminus with variation at position 4 (Arg for cardiac; Leu for bronchial; etc.). This structural family pattern is consistent with the Khavinson gene regulation hypothesis that related sequences target different tissue-specific promoters. Limitless carries it.
Proposed mechanism: AEDL regulates bronchial epithelial cell gene expression, supporting pulmonary tissue maintenance, mucociliary function, and potentially anti-fibrotic effects in lung tissue. The Khavinson group has published animal and tissue culture data on bronchopulmonary peptide bioregulators. Community indication: lung health maintenance, respiratory support, post-inflammatory pulmonary recovery.
Grade C (animal and in vitro; Khavinson group primary). No independent Western RCT. No human clinical trial specifically for Bronchogen. The Khavinson chapter (pbkhavv4) covers the broader bioregulator evidence framework; this chapter provides the compound-specific context for Bronchogen specifically.
Across the Cytogen series including these four compounds: the tissue-specificity principle (that peptides derived from a particular tissue preferentially affect that tissue's cell types) has in vitro support across multiple tissue types. The gene regulation mechanism (short peptides binding DNA promoter elements) has molecular biology support from Khavinson's own research and is pharmacologically plausible — short basic peptides can interact with DNA. The clinical evidence for Cortexin specifically (the approved pharmaceutical) provides the strongest human data point. The overall anti-aging, neuroprotective, and cellular maintenance framework has coherent theoretical grounding.
Independent replication by laboratories not affiliated with Khavinson's program is limited. The specific clinical benefits claimed (cognitive improvement, cardiac protection, joint health, lung support) in healthy community users have not been demonstrated in randomized controlled trials for these specific compounds. The evidence base is heavily single-institution, primarily Russian-language, and primarily in animal/tissue culture models (except Cortexin's clinical data). This does not mean the compounds don't work; it means the evidence cannot be independently quality-graded by Western reviewers to the standards applied to other evidence bases in this book.
Compound
Best Available Evidence
Key Gap
Cortexin
B (limited human)
Russian approval based on clinical trials; 2025 rat I/R model neuroprotection; comparative efficacy with Cerebrolysin/Actovegin in animal models
Single-institution Russian clinical data; limited Western-accessible trials
CardioCytogen (AEDR)
C (animal + in vitro; Khavinson group)
Tissue culture cardiac fibroblast effects (Chalisova 2009); Khavinson gene regulation data; tumor apoptosis observation
No independent Western replication; no human trial; tumor observation requires cancer caution
Crystagen (KEDW)
C (animal + in vitro; Khavinson group)
Khavinson connective tissue culture data; chondrocyte regulation proposal
Least published of the four; no human trial; Western evidence minimal
Bronchogen (AEDL)
C (animal + in vitro; Khavinson group)
Khavinson bronchopulmonary tissue data; structural analogy to other characterized Cytogen peptides
No human trial; community use context (without lung disease) unvalidated
Community use of Khavinson bioregulators typically follows the Cytogen protocol tradition: 2-4 week cycles with rest periods; SubQ injection (most) or intranasal (Cortexin); low doses consistent with the nanomolar-to-micromolar range where tissue culture effects are observed. The absence of established human dose-response data means all community doses are extrapolated from animal models and Khavinson clinical guidelines. Given the tissue-specificity principle, these compounds are used for their specific organ system targets rather than as general performance or recovery compounds.
Both are neuroprotective brain polypeptide extracts but they differ in source tissue (Cortexin = cortex specifically; Cerebrolysin = whole brain), species sourcing, route (Cortexin = IM or intranasal; Cerebrolysin = IV), and evidence base accessibility. Cerebrolysin has more independently replicated Western-accessible trials. Cortexin has Russian pharmaceutical approval for a broader indication set. They are related compounds in the same class — not the same compound.
The defined synthetic tetrapeptides (CardioCytogen, Crystagen, Bronchogen) are the Khavinson group's attempt to identify the minimum active sequence from complex tissue extracts. Whether the simple 4-amino acid peptide fully recapitulates the complex extract's pharmacology is an assumption consistent with the 'minimum active sequence' framework but not definitively validated by head-to-head comparison studies.
Single-institution provenance raises legitimate questions about independence and potential bias in publication and interpretation. It does not make the research fabricated or definitively unreliable. Cortexin's approval by the Russian regulatory authority (Roszdravnadzor) requires clinical evidence meeting regulatory standards, whatever their methodology differences from FDA. The appropriate response is graded skepticism — not dismissal — with explicit evidence grade assignment that reflects the single-institution character of the primary literature.
Khavinson VKh, et al. (2021). Peptide Regulation of Gene Expression: A Systematic Review. Biomedicine & Pharmacotherapy. 134:111120. [Comprehensive review of Khavinson gene regulation hypothesis across the bioregulator series; molecular mechanisms; tissue specificity; the foundational theory document for the Cytogen series.]
Kurkin DV, et al. (2025). Neurotropic Effects of Cortexin on Models of Mental and Physical Developmental Delay. Biomedicines. PMC12024793. [2025 rat study; cortexin in neonatal ischemia-hypoxia and toxic CNS damage models; neuronal survival promotion; comparative with cerebrolysin context.]
Grigoriev AI, et al. (2018). [Molecular mechanisms of brain peptide-containing drugs: Cortexin]. Zhurnal Nevrologii i Psikhiatrii. [Caspase-8 inhibition; molecular partner identification (β5-tubulin, creatine kinase B, protein 14-3-3 α/β); multi-receptor profile (AMPA, kainate, mGluR1, GABA²A1, mGluR5); Russian-language primary paper for Cortexin mechanism.]
Chalisova NI, et al. (2009). Effect of amino acids and Cardiogen on the development of myocardial tissue culture from young and old rats. Advances in Gerontology (Uspekhi Gerontologii). 22(3):409-413. [Primary Cardiogen cardiac tissue culture evidence; young vs old rat myocardial tissue; foundational cardiac bioregulator paper.]
Levdik NV, Knyazkin IV. [Tumor-modifying effect of Cardiogen peptide in rats with transplanted M-1 sarcoma]. St. Petersburg Institute of Bioregulation. [Cardiogen apoptosis induction in sarcoma cells; hemorrhagic necrosis; concentration-dependent tumor growth inhibition; generates cancer context caution.]
See pbkhavv4 for the comprehensive Khavinson bioregulator evidence framework, longevity data, and the broader context of the Russian clinical program.
Four compounds, one research tradition, shared evidence architecture. Cortexin has the strongest evidence by far. The three tetrapeptides (AEDR, KEDW, AEDL) rest on the same Khavinson framework with less published data each.
The compounds in this cluster are best understood as part of a research program rather than as standalone pharmacological entities with independent validation. The Khavinson bioregulator tradition has produced one approved pharmaceutical (Cortexin) with real clinical evidence. The defined synthetic tetrapeptides (CardioCytogen, Crystagen, Bronchogen) carry Grade C evidence from tissue culture and animal models within a single research institution. For anyone using these compounds, the tissue-specificity principle is pharmacologically coherent, the evidence is real but limited, and the honest grade assignment (B for Cortexin; C for the three tetrapeptides) should guide expectation setting.
— End of Khavinson Bioregulator Cluster —
THE PEPTIDE BIBLE | Khavinson Bioregulator Cluster | For Research & Educational Purposes Only
KHAVINSON BIOREGULATOR CLUSTER: Four organ-specific bioregulators from the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson group). Shared framework: tissue-specific short peptides regulate gene expression via DNA promoter interaction; organ-specific compounds for organ-specific effects. CORTEXIN: Lyophilized polypeptide extract from bovine/porcine cerebral cortex (Geropharm); MW 1,000-10,000 Da heterogeneous mixture; Russian-approved (stroke, TBI, encephalopathy, epilepsy, cognitive disorders, pediatric delay); multi-receptor (AMPA, kainate, mGluR1, GABA²A1, mGluR5); molecular partners β5-tubulin, creatine kinase B, 14-3-3 α/β; 2025 rat I/R neuroprotection confirmed; comparable to Cerebrolysin in animal models; Grade B (limited human; Russian approval); Limitless; intranasal 0.5-3 mg/day community; IM standard clinical route; Cortexin ≠ Cerebrolysin (different source tissue, route, evidence base). CARDIOCYTOGEN (Cardiogen): Ala-Glu-Asp-Arg (AEDR); tetrapeptide; MW ~430 Da; cardiac fibroblast modulator; cardiomyocyte proliferation effects in rat tissue culture (Chalisova 2009); collagen/elastin synthesis modulation; tumor apoptosis observation in M-1 sarcoma (Levdik/Knyazkin); Grade C; no human trial; Limitless 20mg vials; CAUTION for cancer history (apoptosis/fibroblast modulation). CRYSTAGEN (KEDW): Lys-Glu-Asp-Trp; connective tissue/cartilage bioregulator; chondrocyte regulation; joint health indication; Grade C; Xcells; no human trial; least published of the four. BRONCHOGEN (AEDL): Ala-Glu-Asp-Leu; bronchial/pulmonary bioregulator; note structural analogy to Cardiogen (AEDR) with Leu vs Arg at position 4; pulmonary epithelial regulation; lung maintenance indication; Grade C; Limitless; no human trial. SHARED EVIDENCE ISSUES: All four from single institution (Khavinson group); Russian-language primary publications; limited Western independent replication; Cortexin has regulatory approval evidence; the three tetrapeptides do not. COMPANION: pbkhavv4 for broader Khavinson framework and longevity data.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.